Roy S. Herbst, MD, PhD, on Lung Cancer With Immune Checkpoints: Promising Combinations

2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Tweet this page

Roy S. Herbst, MD, PhD, of the Yale Cancer Center, discusses immunotherapy as a standard of care in lung cancer, critical biomarkers, and scientifically guided combination treatment, which will be the future of lung cancer immunotherapy.

Advertisement

Advertisement



Advertisement